Get started
Author

Michaela Ferrer

Observed name: M. Ferrer
Observed institution: aTyr Pharma (United States)
ORCID: 0009-0007-5641-8210
Observed ORCID: 0009-0007-5641-8210
OpenAlex ID: A5031837675
A human histidyl-tRNA synthetase splice variant therapeutic targets NRP2 to resolve lung inflammation and fibrosis
2025 · Leslie A. Nangle, Zhiwen Xu, et al. · Science Translational Medicine · 16
Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune Cells
2020 · S. Paz, D. Chu, et al. · American Journal of Respiratory and Critical Care Medicine · 5
Late Breaking Abstract - Immunomodulatory protein ATYR1923 disrupts an in vitro model of sarcoid granuloma formation
2021 · Suzanne Paz, Mark W. Julian, et al. · European Respiratory Journal · 4
Efzofitimod: a novel therapeutic candidate for SSc-ILD
2023 · David Siefker, Zhiwen Xu, et al. · European Respiratory Journal · 2
699 ATYR2810 an anti-NRP2 monoclonal antibody targets tumor-associated macrophages
2021 · Samantha Tyler, Michaela Ferrer, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Efzofitimod, a Novel Immunomodulator for Pulmonary Sarcoidosis, Modulates Patient Inflammatory Responses Through Myeloid Cells
2023 · D. Siefker, S. Paz, et al. · American Journal of Respiratory and Critical Care Medicine
Works count: 6
Citation count: 28
H-index: 3
I10-index: 1
Year
Topic
Type